Rani Therapeutics (RANI) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update First Quarter 2025 Highlights: Near-Term Milestone Expectations: • Initiation of Phase 1 clinical trial of RT-114 for the treatment of obesity expected in mid-2025. First Quarter 2025 Financial Results: • Preclinical data demonstrating bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneously administered PG-102. In March 2025 ...